Previous 10 | Next 10 |
Trading to begin November 18, 2021 with current ticker "ANVS" Berwyn, Pennsylvania--(Newsfile Corp. - November 15, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (P...
With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's...
Biogen's struggles with Aduhelm - its newly approved Azheimer's therapy - have been well documented - but the company is taking some small steps in the right direction. Meanwhile, Cassava Sciences recently took a significant step to restoring its own reputation - and share price - aft...
Poster highlighting the mechanism of action for ANVS401 is on display onsite and online Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD...
Pioneer Power Solutions (NASDAQ:PPSI) +46% launches E-Boost - smart, mobile EV charging solutions Autolus Therapeutics (NASDAQ:AUTL)+26% on securing $250M strategic funding from Blackstone The Trade Desk (NASDAQ:TTD) +23% on Q3 earnings. Volta(NYSE:VLTA) +19%. Gaotu Techedu (NYSE:GO...
Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. EST A poster highlighting the mechanism of action for ANVS401 will be on display onsite and online Berwyn, Pennsylvania--(Newsfile Corp. - November 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) (...
Peter Bensen purchases shares of Lamb Weston for the second time since he joined the board. Lamb Weston's revenue jumped double digits to around $1 billion during the last two quarters. CEO of C3.ai continues selling under 10b5-1 trading plan. For further details see: In...
Gainers: Grove (NASDAQ:GRVI) +62%. NRx Pharmaceuticals (NASDAQ:NRXP) +35%. Connect Biopharma (NASDAQ:CNTB) +23%. Huttig Building Products (NASDAQ:HBP) +20%. KORE (NYSE:KORE) +20%. DarioHealth (NASDAQ:DRIO) +19%. Broadwind (NASDAQ:BWEN) +19%. Cemtrex (NASDAQ:CETX) +17%. Annovis (NYSE:ANVS) +17...
Gainers: Grove (NASDAQ:GRVI) +63%, NRx Pharmaceuticals (NASDAQ:NRXP) +34%, DarioHealth (NASDAQ:DRIO) +22%, Connect Biopharma (NASDAQ:CNTB) +21%, Annovis Bio (NYSE:ANVS) +15%. Losers: Jasper Therapeutics (NASDAQ:JSPR) -20%, PLx Pharma (NASDAQ:P...
On Tuesday Oct 5, ANVS announced the results from their phase 2 dose-ranging study in Parkinson's Disease. Responding to the news, the stock declined by >13% to close at $26.35 from the previous close. I take a look at the data and share my thoughts here. For further deta...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...